Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Constance CareWAR:CCR 20 EV-to-EBIT is -608.61 as of Aug. 12, 2026. GuruFocus rates WAR:CCR with a GF Score™ of 20/100 and a GF Value™ of zł0.15 (Significantly Overvalued). Among 473 Healthcare Providers & Services companies, Constance Care ranks worse than 211416.28% on this metric.
The historical rank and industry rank for Constance Care's EV-to-EBIT or its related term are showing as below:
WAR:CCR'
s EV-to-EBIT Range Over the Past 10 Years
Min: -608.61 Med: 24.84 Max: 502.48
Current: -608.61
During the past 6 years, the highest EV-to-EBIT of Constance Care was 502.48. The lowest was -608.61. And the median was 24.84.
WAR:CCR's EV-to-EBIT is ranked worse than 100% of 473
companies
in the Healthcare Providers & Services industry
Industry Median: 15.84
vs WAR:CCR: -608.61
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Constance Care's Enterprise Value for the quarter that ended in Mar. 2026 was zł21.43 Mil.
Constance Care's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-0.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Constance Care EV-to-EBIT Related Terms
Constance Care EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Constance Care's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Constance Care's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Constance Care EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Constance Care's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Constance Care's EV-to-EBIT falls into.
Constance Care's current Enterprise Value is zł18.87 Mil.
Constance Care's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-0.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Constance Care (WAR:CCR) has a EV-to-EBIT of -608.61 as of Aug. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Constance Care and its competitors. According to the industry distribution chart, Constance Care ranks #999999 out of 473 companies in the Healthcare Providers & Services industry.
Is Constance Care's EV-to-EBIT too high?
Constance Care's current EV-to-EBIT is -608.61. Based on the distribution chart, Constance Care ranks #999999 out of 473 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Constance Care has a GF Score™ of 20/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Constance Care's EV-to-EBIT compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Constance Care ranks #999999 out of 473 companies for EV-to-EBIT. This places Constance Care in the lower half of its industry. The industry median EV-to-EBIT is 15.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.84, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Constance Care and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Constance Care's current EV-to-EBIT is -608.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Constance Care stock overvalued right now?
Based on GuruFocus' analysis, Constance Care (WAR:CCR) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.15, compared to a current price of zł5.20 — trading 3366.7% above its estimated fair value. The current EV-to-EBIT is -608.61. Constance Care's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Constance Care (WAR:CCR), the current EV-to-EBIT is -608.61 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Constance Care (WAR:CCR) Overvalued in 2026?
Based on GuruFocus' analysis, Constance Care stock appears to be overvalued.
The current stock price of zł5.20 is trading 3366.7% above its estimated GF Value™ of zł0.15.
GuruFocus considers Constance Care to be Significantly Overvalued.
Key valuation signals for WAR:CCR:
EV-to-EBIT: -608.61
GF Value™: zł0.15 vs. price of zł5.20 (3366.7% above fair value)
No single metric tells the full story. See the WAR:CCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Constance Care SA conducts physiotherapeutic activities aimed at improving the quality of health and life of people suffering both from musculoskeletal disorders as a result of various random events, diseases or related to the aging of the body, as well as the rehabilitation of cognitive functions in children and adults.
20GF Score
Get the complete analysis for WAR:CCR
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:CCR has been successfully added to your 
